Cantor Fitzgerald Equity Opportunity Fd earns a Low Process Pillar rating. The main detractor from the rating is the fund's unimpressive long-term risk-adjusted performance. This can be seen in ...

Cantor Fitzgerald Large Cap Focused Fund earns an Above Average Process Pillar rating. The leading factor in the rating is the parent firm's five-year risk-adjusted success ratio of 81%.

On Wednesday, Cantor Fitzgerald maintained an Overweight rating on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), following the company’s recent webinar that focused on its launch strategy for ...

On Thursday, Cantor Fitzgerald reaffirmed its Overweight rating on shares of Summit Therapeutics plc (NASDAQ:SMMT), a biopharmaceutical company. According to InvestingPro data, the stock currently ...

Artiva Biotherapeutics (NASDAQ:ARTV – Free Report) had its price target cut by Cantor Fitzgerald from $23.00 to $20.00 in a research note published on Tuesday,Benzinga reports. They currently ...

Protara Therapeutics, Inc. (NASDAQ:TARA – Free Report) – Stock analysts at Cantor Fitzgerald dropped their FY2025 EPS estimates for Protara Therapeutics in a research note issued on Thursday ...

This decision is seen as a pivotal step for Lucid Diagnostics, potentially expanding the availability and financial support for the test among Medicare beneficiaries.Cantor Fitzgerald’s reiterated ...

On Tuesday, Cantor Fitzgerald reiterated its Overweight rating on Meta Platforms Inc. (NASDAQ:META) with a price target of $790.00, well above the current trading price of $618.85. The firm’s ...

At close: 4:10:02 PM GMT+11 Loading Chart for WTC.AX ...